Advertisement


Andres Poveda, MD, on Ovarian Cancer: Assessing Maintenance Olaparib

ASCO20 Virtual Scientific Program

Advertisement

Andres Poveda, MD, of Initia Oncology, discusses phase III results from the SOLO2 trial, which showed that, compared with placebo, maintenance olaparib improved median overall survival by 12.9 months in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (Abstract 6002).



Related Videos

Leukemia
Myelodysplastic Syndromes

Mikkael A. Sekeres, MD, on MDS, CMML, or AML: Pevonedistat and Azacitidine

Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses data from a phase II study of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia (Abstract 7506).

Bladder Cancer
Immunotherapy

Metastatic Urothelial Cancer: A Conversation on State-of-the-Art Treatment Before the ASCO20 Virtual Scientific Program

As Thomas Powles, MD, PhD, of Queen Mary University of London, prepares to deliver his late-breaking presentation at the ASCO20 Virtual Scientific Program (LBA-1), he talks with Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, about current therapy: PD1/PDL1 inhibition in second-line treatment and as monotherapy in the first-line setting, as well as the concept of maintenance switch.

Bladder Cancer
Immunotherapy

Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Urothelial Cancer: The JAVELIN Bladder 100 Study on Avelumab vs Best Supportive Care

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, talks with Thomas Powles, MD, PhD, of Queen Mary University of London, about the first study to demonstrate a survival advantage with avelumab for metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared with 14.3 months with best supportive care (Abstract LBA1).

Head and Neck Cancer

Christopher Nutting, MD, PhD, on Head and Neck Cancer: Dysphagia-Optimized vs Standard IMRT

Christopher Nutting, MD, PhD, of the Royal Marsden Hospital and Institute of Cancer Research, discusses phase III results from the first study to demonstrate the functional benefit of swallow-sparing intensity-modulated radiotherapy in oro- and hypopharyngeal cancers (Abstract 6508).

Lung Cancer
Immunotherapy

Egbert F. Smit, MD, PhD, on NSCLC: Treatment With Fam-trastuzumab Deruxtecan

Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses interim results from the DESTINY-Lung01 trial of fam-trastuzumab deruxtecan in patients with HER2-mutated metastatic non–small cell lung cancer. The data show clinical activity with high overall response rates and durable responses (Abstract 9504).

Advertisement

Advertisement




Advertisement